SCHEMBL4914009

SCHEMBL4914009

NS(=O)(=O)c1cc(Nc2c(NCc3cccc(O)c3)c(=O)c2=O)ccc1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.45
MAPKAPK2 P49137 1/20 0.44
GSK3B P49841 7/20 0.43
ROCK1 Q13464 7/20 0.43
PKN2 Q16513 7/20 0.43
AURKB Q96GD4 7/20 0.43
CLK4 Q9HAZ1 6/20 0.43
ROCK2 O75116 5/20 0.43
PRKG2 Q13237 5/20 0.43
NEK4 P51957 5/20 0.43
CLK2 P49760 4/20 0.43
MAP4K4 O95819 4/20 0.43
PRKX P51817 3/20 0.43
PBK Q96KB5 2/20 0.43
SLK Q9H2G2 2/20 0.43
EEF2K O00418 1/20 0.43
TAOK1 Q7L7X3 1/20 0.43
MAP3K20 Q9NYL2 1/20 0.43
HIF1A Q16665 1/20 0.43
CHEK2 O96017 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4917069 0.82 EGFR (0.50) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4919796 0.82 GSK3B (0.48) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4906887 0.81 MAPKAPK2 (0.54) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4916629 0.81 EGFR (0.49) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4916045 0.80 EGFR (0.57) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4909188 0.80 CA2 (0.50) MAPKAPK2GSK3BROCK1PKN2AURKB
SCHEMBL4917914 0.80 EGFR (0.46) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4599292 0.79 HIF1A (0.48) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4913266 0.79 ROCK2 (0.53) EGFRMAPKAPK2GSK3BROCK1PKN2
SCHEMBL4909304 0.79 EGFR (0.47) EGFRMAPKAPK2GSK3BROCK1PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US claimed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP claimed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO claimed
US-20080262096-A1 Squaric Acid Derivatives MERCK PATENT GMBH (DE) 2008-10-23 US disclosed
EP-1838662-A1 SQUARIC ACID DERIVATIVES Merck Patent GmbH (DE) 2007-10-03 EP disclosed
WO-2006072354-A1 SQUARIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262096-A1 Squaric Acid Derivatives GLS, SGK1, PFKL EGFR 2751/4885MAPKAPK2 1309/4885GSK3B 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.